Related Experiment Video

Updated: Apr 18, 2026

Generation of Fluorescent Protein Fusions in Candida Species
09:27

Generation of Fluorescent Protein Fusions in Candida Species

Published on: March 4, 2017

11.3K

Update on the management of Candida infections in preterm neonates

P Manzoni1, M Mostert2, E Castagnola3

  • 1Department of Neonatology and NICU, S. Anna Hospital, Torino, Italy.

Archives of Disease in Childhood. Fetal and Neonatal Edition
|January 22, 2015
PubMed

Insights

Preventing invasive fungal infections in preterm neonates is crucial. This review explores optimal antifungal strategies for high-risk infants, focusing on drug selection for better outcomes.

Area of Science:

  • Neonatal Intensive Care Unit (NICU) Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) in preterm neonates, primarily caused by Candida species, lead to significant morbidity and mortality in the NICU.
  • While prophylactic strategies are emerging, optimizing management for high-risk infants remains a critical challenge.
  • Effective antifungal therapy requires careful consideration of neonatal factors, local epidemiology, and drug pharmacokinetics.

Purpose of the Study:

  • To review the current state of knowledge regarding neonatal fungal infections.
  • To identify ideal characteristics of antifungal drugs for preterm neonates.
  • To address key questions concerning optimal prophylactic and therapeutic strategies for this vulnerable population.

Main Methods:

  • Literature review of current research on neonatal IFIs.
  • Analysis of antifungal drug properties relevant to preterm infants.
  • Discussion of epidemiological data and pharmacokinetic considerations.

Main Results:

  • Ideal antifungal agents should target fungal biofilms, treat end-organ infections, and combat fluconazole-resistant Candida strains.
  • Safety and tolerability are paramount for antifungal drug selection in neonates.
  • The review synthesizes current evidence to guide clinical practice.

Conclusions:

  • Optimizing antifungal prophylaxis and treatment in preterm neonates is essential for reducing IFIs.
  • Careful drug selection based on specific neonatal and fungal characteristics is necessary.
  • Further research is needed to refine strategies for managing fungal infections in this high-risk group.
Keywords:
CandidaFluconazoleInfectious DiseasesNeonatologyPreterm

More Related Videos

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

6.0K
Author Spotlight: Photodynamic Therapy as a Novel Approach to Induce Petite Colonies in Drug-Resistant Candida for Antifungal Research09:06

Author Spotlight: Photodynamic Therapy as a Novel Approach to Induce Petite Colonies in Drug-Resistant Candida for Antifungal Research

Published on: March 29, 2024

1.2K

Related Concept Videos

Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
46
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
103
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
71
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
50
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
656